Off-Label Communications: US FDA Won't Impede Discussions With Payers, Gottlieb Says
Executive Summary
Guidance, to be issued 'very soon,' will provide a safe harbor for discussions between manufacturers and payers about off-label drug uses, Commissioner Scott Gottlieb says.
You may also be interested in...
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.
Off-Label Communication: When Does It Align With Approved Labeling?
US FDA draft guidance offers three-factor test to determine when communication about a medical product is consistent with labeling; information on patient-reported outcomes and mechanism of action are okay.
Biogen’s Plea To Medicare: Just Cover The Aduhelm Clinical Trial Population
Company discusses its strategy for negotiating a change in the recently-proposed Medicare coverage decision for Alzheimer’s drugs during a presentation to analysts.